Who are SPN-810 (36 mg)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Lithobid, Tegretol, CARBAMAZEPINE, valproate microgranules, Placebo plus Lithium, Divalproex (DV).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/spn-810-36-mg.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

SPN-810 (36 mg) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SPN-810 (36 mg) (SPN-810 (36 mg)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: mood stabilizer. Area: Psychiatry.

phase 3 mood stabilizer Psychiatry Small molecule Live · refreshed every 30 min

Target snapshot

SPN-810 (36 mg) (SPN-810 (36 mg)) — Supernus Pharmaceuticals, Inc.. SPN-810 is a proprietary formulation of a divalproex sodium extended-release product designed to treat disruptive mood dysregulation disorder (DMDD).

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
SPN-810 (36 mg) TARGET	SPN-810 (36 mg)	Supernus Pharmaceuticals, Inc.	phase 3	mood stabilizer
Lithobid	lithium carbonate	Generic (multiple manufacturers)	marketed	Mood stabilizer	Inositol-1(or 4)-monophosphatase 1, Glycogen synthase kinase-3	1970-04-06
Tegretol	carbamazepine	Novartis AG (originally Geigy)	marketed	Mood Stabilizer [EPC]	Frizzled-8, Nuclear receptor subfamily 1 group I member 2, Neuronal acetylcholine receptor; alpha2/beta4	1968-03-11
CARBAMAZEPINE	CARBAMAZEPINE		marketed	Mood Stabilizer [EPC]		1968-01-01
valproate microgranules	valproate microgranules	Sanofi	marketed	Anticonvulsant / Mood stabilizer	Histone deacetylase; GABA metabolism
Placebo plus Lithium	Placebo plus Lithium	Shanghai Mental Health Center	marketed	Mood stabilizer	GSK-3 (glycogen synthase kinase-3), inositol monophosphatase
Divalproex (DV)	Divalproex (DV)	Weill Medical College of Cornell University	marketed	Histone deacetylase inhibitor; anticonvulsant; mood stabilizer	Histone deacetylase; GABA metabolism; sodium and calcium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2028-11-10 — Tegretol · 9770407 · Formulation · US
2028-11-10 — Tegretol · 9629797 · Method of Use · US
2029-03-13 — Tegretol · 9750822 · Formulation · US
2029-03-13 — Tegretol · 7635773 · Formulation · US
2029-03-13 — Tegretol · 8410077 · Formulation · US
2033-02-27 — Tegretol · 9493582 · Formulation · US
2040-01-31 — Tegretol · 11529357 · Formulation · US

Sponsor landscape (mood stabilizer class)

AstraZeneca · 1 drug in this class
Sanofi · 1 drug in this class
Supernus Pharmaceuticals, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). SPN-810 (36 mg) — Competitive Intelligence Brief. https://druglandscape.com/ci/spn-810-36-mg. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing